Elevance Health Inc. (NYSE:ELV) is one of the most undervalued large cap stocks to invest in now.. On January 30, Barclays lowered the firm’s price target on Elevance Health to $393 from $404 and kept an Overweight rating on the shares. On January 29, Guggenheim analyst Jason Cassorla also lowered the firm’s price target on Elevance Health to $396 from $414 and maintained a Buy rating on recalibrated 2026 estimates following the company’s Q4 2025 report. However, on the same day, Deutsche Bank raised the ...

Core Insights - Elevance Health Inc (NYSE:ELV) experienced its largest single-day percentage gain since May 2024, reporting profits of $547 million, although this was not sufficient to recover from its worst day since March 2020 due to proposed Medicare Advantage payment rate increases of only 0.09% for 2027 [1] - The stock is currently near a trendline with historically bullish implications, which may assist in reducing its 14.2% year-over-year deficit [1] Technical Analysis - According to Schaeffer's Senior Quantitative Analyst, ELV is within 0.75 of its 100-day moving average's 20-day average true range (ATR), having remained above this level 80% of the time over the last two weeks and 80% of the past 42 trading sessions. This pattern has historically led to an average gain of 5.7% one month later [3] - A similar upward movement from the current position could push ELV back above $363 [3] Market Sentiment - The health insurance stock's 50-day put/call volume ratio at major exchanges is higher than 99% of annual readings, indicating that an unwinding of pessimism could provide positive momentum for the shares [4] - Options for ELV are currently affordably priced, with a Schaeffer's Volatility Index (SVI) of 33% ranking in the 27th percentile of annual readings, suggesting that the stock has exceeded option traders' volatility expectations over the past year [5]

Key Takeaways Elevance Health posted Q4 adjusted EPS of $3.33, beating consensus by 7.3% despite revenues missing estimates.ELV's premiums rose 12.3% year over year, driven by higher yields and Medicare Advantage membership growth.Carelon revenues jumped 27% on buyouts and risk-based services, while overall medical membership declined.Elevance Health, Inc. (ELV) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $3.33, which surpassed the Zacks Consensus Estimate by 7.3%. The bottom line rose ...

Elevance Health Earnings Add to Medicare Pain. Why The Stock Is Rising Anyway. - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# Elevance Health Earnings Add to Medicare Pain. Why The Stock Is Rising Anyway.By [Mackenzie Tatananni]and [Alex K ...

The author has an honours degree in economics and politics with a focus on economic development. With 36 years of experience in executive management he has extensive knowledge of insurance/reinsurance, Global and Asia Pacific markets, climate change and ESG. He invests in his personal capacity.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and ...

By Sriparna Roy and Sneha S K Jan 28 (Reuters) - Elevance Health said on Wednesday it expects revenue to fall slightly in 2026 and forecast full-year profit below Wall Street estimates, signaling that elevated medical costs will continue to weigh on insurers. The dour outlook ​sent shares of the health insurer down more than 7% before the bell. “We view 2026 as a year of execution and repositioning ‌across Medicaid, Medicare Advantage and (Obamacare plans),” said CEO Gail Boudreaux, adding the forecas ...

Second, even in a dynamic environment, we are acting decisively in the areas within our control to strengthen margins, reduce volatility, and improve the consistency of our performance. And third, as those actions take hold, we expect to return to at least 12% adjusted EPS growth in 2027 off our ending 2026 earnings baseline supported by the earnings power of our diversified platform. Consistent with that approach, we are establishing 2026 adjusted diluted earnings per share guidance of at least $25.50. As ...

CFO Mark Kaye reported adjusted diluted EPS of $3.33 for the fourth quarter and $30.29 for the full year. He said fourth-quarter results benefited from greater tax favorability than anticipated, increasing the full-year contribution from non-recurring items to $3.75 per share . Kaye added that solid underlying performance allowed the company to advance some investments originally planned for 2026 and to support workforce-related initiatives entering the year.Elevance Health established 2026 adjusted diluted ...

Elevance Health Inc. (NYSE:ELV) shares fell after the health insurer reported mixed fourth-quarter 2025 earnings and bleak fiscal 2026 guidance. The stock has recovered most of its loss from the premarket sessionEarnings SnapshotThe company reported fourth-quarter 2025 revenues of $49.3 billion, up 10% year over year, below the consensus of $49.82 billion. Operating revenue was $197.6 billion in 2025, up 13%.The increase in revenue for the quarter and year was driven by higherpremium yields in the Health Be ...

Elevance Health (NYSE:ELV) Q4 2025 Earnings call January 28, 2026 08:30 AM ET Company ParticipantsA.J. Rice - Managing Director and Equity ResearchAndrew Mok - Director, Equity ResearchBen Hendrix - VP and Assistant VPDave Windley - Managing DirectorFelicia Norwood - President, Government Health BenefitsGail Boudreaux - President and CEOLisa Gill - Managing DirectorMark Kaye - CFOMorgan Kendrick - President, Commercial Health BenefitsNathan Rich - VP of Investor RelationsPete Haytaian - President of Carelon ...